Fundraising Fox
AbbVie
NYSE: ABBVNorth Chicago, US · Founded 2012 · Delaware corporation · 2 known investors
Find your way into AbbVie
Sign up to see every warm intro you have to AbbVie
- Paths you didn't know you had: your email and LinkedIn already hold routes to the AbbVie team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
AbbVie develops and sells biopharmaceutical therapies across immunology, neuroscience, oncology, and aesthetics, addressing autoimmune diseases, neurologic conditions, blood cancers, and cosmetic applications through products like Skyrizi, Rinvoq, Humira, Vraylar, Imbruvica, and Botox.
Founders & leadership
Board
Investors · 2
How we know: offering press articles · Not right? Tell us
How we know: offering press articles · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$3.8B disclosed across 1 round · 2016
▶$3.8BraisedMay 2016 · 39 investors · PharmaceuticalsRule 506(b)
- Thomas A. HurwichExecutive Officer
- Edward M. LiddyDirector
- Timothy J. RichmondExecutive Officer
- Glenn F. TiltonDirector
- Henry GosebruchExecutive Officer
- Azita Saleki-GerhardtExecutive Officer
- Roxanne S. AustinDirector
- Michael E. SeverinoExecutive Officer
- Frederick H. WaddellDirector
- William ChaseExecutive Officer
- Richard A. GonzalezExecutive Officer, Director
- Robert J. AlpernDirector
- William H.L. BurnsideDirector
- Brett J. HartDirector
- Carlos AlbanExecutive Officer
- Edward RappDirector
- Laura J. SchumacherExecutive Officer
- Offering amount
- $3.8B
- Amount sold
- $3.8B
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Acquisitions · 3
Early investors' stakes continue via these dealsAliada Therapeutics was a Boston-based clinical-stage biotech developing its MODEL platform to transport therapeutic antibodies across the blood-brain barrier for CNS diseases. Its lead candidate, an anti-amyloid-beta antibody, targeted Alzheimer's disease.
Combines single-cell RNA analysis technology from the Broad Institute with AI/ML models and large-scale clinical sample collection for novel drug discovery and precision medicine. Acquired by AbbVie Inc. in June 2024.
Gilgamesh Pharmaceuticals was a New York-based clinical-stage neuroscience biotech developing psychedelic-derived and NMDA-receptor compounds for psychiatric disorders like major depressive disorder.
Frequently asked questions
- What does AbbVie do?
- AbbVie develops and sells biopharmaceutical therapies across immunology, neuroscience, oncology, and aesthetics, addressing autoimmune diseases, neurologic conditions, blood cancers, and cosmetic applications through products like Skyrizi, Rinvoq, Humira, Vraylar, Imbruvica, and Botox.
- Who are AbbVie's investors?
- AbbVie's investors include Artis Ventures, Founders Fund.
- How much funding has AbbVie raised?
- AbbVie has disclosed $3.8B raised across 1 round.
- Where is AbbVie headquartered?
- AbbVie is headquartered in North Chicago, US.